Figure 1
Trial Flow Diagram. A total of 1,212 eligible patients underwent laboratory assays and ultrasonography at baseline. Among them, 1008 participants (499 and 509 in the TXL and placebo group, respectively) completed the study follow-up.
Figure 1 | Scientific Reports
